PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS
Brief description of study
The purpose of this research study is to evaluate the safety of the study drug, tofacitinib (CP-690,550-10) at two doses (5mg and 10mg) compared to a tumor necrosis factor inhibitor (TNFi) drug (adalimumab in the US, Puerto Rico and Canada and etanercept in all other countries). These drugs affect the immune system. The immune system normally fights infection, but in diseases like RA, the immune system may be overactive or act incorrectly, leading to inflammation, swelling and pain. These drugs are known as disease-modifying antirheumatic drugs (DMARDS) for the treatment of RA.
Clinical Study Identifier: s18-00241
ClinicalTrials.gov Identifier: NCTs18-00241
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
